Conmed Corp (CNMD) Reports In-Line Q2 EPS; Guides Q3
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $49.25 -2.3%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Conmed Corp (NASDAQ: CNMD) reported Q2 EPS of $0.35, in-line with the analyst estimate of $0.35. Revenue for the quarter came in at $183.2 million versus the consensus estimate of $185.81 million.
Conmed Corp sees Q3 2011 EPS of $0.29-$0.33, versus the consensus of $0.33. Sees revs down slightly sequentially.
Conmed Corp sees Q3 2011 EPS of $0.29-$0.33, versus the consensus of $0.33. Sees revs down slightly sequentially.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- InspireMD (NSPR) Tops Q2 EPS by 1c
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
